HHT-109

Primary Objective: To evaluate the safety and tolerability of HHT109 capsules in healthy participants after single and multiple administrations. To determine the median dose (MTD) of HHT109 capsules in healthy participants as a single oral dose, providing a safe dosage range for later clinical trials. Secondary Objectives: To evaluate the pharmacokinetic characteristics of HHT109 capsules in healthy participants after single and multiple administrations; to evaluate the pharmacokinetic characteristics of HHT109 capsules administered in healthy participants under fasting and postprandial conditions; and to evaluate the effect of food on pharmacokinetic characteristics. Exploratory Objectives: To evaluate the pharmacodynamic and pharmacokinetic characteristics of HHT109 capsules in healthy participants after single and multiple administrations; and to evaluate the effect of HHT109 capsules on the QT interval in healthy participants after single and multiple administrations.